Scores

Etiology

Suspected MASLD patients (Formerly NAFLD)

Target

MASH + NAS≥4 + F≥2

Uses

Screening for clinical trial and identifying at-risk MASH patients

FibroScan^® results (LSM by VCTE™ & CAP™) + laboratory parameter (AST)

Reference

Fast is a formula published and validated in multiple studies. Fast: princeps paper - Newsome et al., Lancet

Etiology

Suspected MASLD patients

Target

F≥3

Uses

Identifying MASLD patients with advanced fibrosis and predicting risk of complications

LSM by VCTE™ + Clinical parameters (AST, ALT, Platelets, Presence of Diabetes, Age and Gender)

Reference

Agile 3+: Princeps paper - Sanyal et al., Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan based Agile scores, Journal of Hepatology, 2022Gastroenterology Hepatology 2020;5(4):362-73

Etiology

Suspected MAFLD patients

Target

F4

Uses

Identifying MAFLD patients with cirrhosis that need to be screen for HCC

LSM by VCTE™ + Clinical parameters (AST, ALT, Platelets, Presence of Diabetes and Gender)

Reference

Agile 4: Princeps paper - Sanyal et al., Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan based Agile scores, Journal of Hepatology, 2022Gastroenterology Hepatology 2020;5(4):362-73